Drugs in Dev. Infections and Infectious Diseases
Phase I
Israel 
Lead Product(s) : LD PepGNP-SARSCoV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Emergex Vaccines Holding
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NanoPass is partnering with Emergex for multiple COVID vaccine LD PepGNP-SARSCoV2, to demonstrate that its drug delivery platform, the MicronJet® 600 can reduce the dose of any vaccine as well as improve immune responses using equivalent doses.
Product Name : LD PepGNP-SARSCoV2
Product Type : Vaccine
Upfront Cash : Inapplicable
January 26, 2022
Lead Product(s) : LD PepGNP-SARSCoV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Emergex Vaccines Holding
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
Details : ALLOCETRATM has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with ...
Product Name : Allocetra-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
Details : ALLOCETRATM targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tum...
Product Name : Allocetra-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data from the studies demonstrate the ability of AllocetraTM to broadly resolve cytokine storm-associated organ failure and reduce mortality by 90% in a murine cecal ligation and puncture (CLP) animal model of severe sepsis.
Product Name : Allocetra-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary aim of the clinical trial was to determine the safety profile and tolerability of Off-The-Shelf Allocetra in Patients with Severe Sepsis.
Product Name : Allocetra-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enlivex has publicly announced its plan to initiate in 2020 two clinical studies: (i) a Phase II/III clinical trial for sepsis later in the year, and (ii) a Phase II/III for the prevention of GvHD.
Product Name : Allocetra
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : Allocetra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
